
Opinion|Videos|January 24, 2025
Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024
Author(s)Thomas W. LeBlanc, MD, MA
Thomas W. LeBlanc, MD, MA, discusses how treatment regimens for low-risk myelodysplastic syndromes (LR-MDS) significantly impact health-related quality of life (HRQOL), with data from the COMMANDS study (Oliva et al, ASH 2024, Abstract 3216) highlighting the correlation between HRQOL and clinical end points, and explore how incorporating HRQOL data into clinical decision-making can guide more patient-centered treatment choices in community settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do treatment regimens impact HRQOL in LR-MDS?
- Please review and discuss HRQOL from COMMANDS: Oliva et al, ASH 2024, Abstract 3216.
- How do HRQOL data correlate with clinical end points?
- How can HRQOL data impact treatment choices in the community?
Advertisement
Related to this article

During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.

Ongoing phase 3 research will help clarify the long-term benefit of amivantamab in head and neck squamous cell carcinoma.

iSCIB1+ advances toward a global phase 3 trial in advanced melanoma, with closer guidance from the FDA.

The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.

FDA approval of pimicotinib adds another CSF1R inhibitor for tenosynovial giant cell tumor, says Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute.

The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
2
FDA Removes PCNSL Limitation From Liso-Cel Label
3
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastric Cancer
4
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
5

